

CITATION REPORT

List of articles citing

Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group

DOI: PM/3749928

Seminars in Hematology, 1986, 23, 177-82.

Source: <https://exaly.com/paper-pdf/127586238/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
312	Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. 1987 , 25, 191-201		49
311	Essential thrombocythaemia and the Philadelphia chromosome. 1988 , 70, 13-9		49
310	Essential thrombocythemia and pregnancy. 1988 , 28, 66		8
309	Essential thrombocythemia. Clinical characteristics and course of 61 cases. 1988 , 61, 2487-96		166
308	[Clinical characterization of essential thrombocythemia in comparison to other myeloproliferative diseases and reactive thrombocytoses]. 1988 , 66, 699-702		
307	[Clinical characterization of essential thrombocythemia in comparison with other myeloproliferative diseases and reactive thrombocytoses]. 1988 , 66, 190-8		5
306	[Thrombocyte function in essential thrombocythemia and reactive thrombocytosis]. 1988 , 66, 199-207		4
305	Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia. 1988 , 413, 407-17		34
304	Alpha-interferon therapy for essential thrombocythaemia. 1988 , 2, 70-2		87
303	Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. 1988 , 94, 1063-9		195
302	Preleukemic syndromes and other syndromes predisposing to leukemia. 1988 , 35, 853-71		9
301	The Bone Marrow in Myeloproliferative and Dysmyelopoietic Syndromes. 1988 , 2, 669-694		8
300	Ultrastructural analysis of platelets and megakaryocytes from a dog with probable essential thrombocythemia. 1989 , 26, 289-93		4
299	[Megakaryocytic myelosis--clinical aspects, morphology and platelet function]. 1989 , 67, 51-9		2
298	The application of X-chromosome gene probes to the diagnosis of myeloproliferative disease. 1989 , 72, 530-3		48
297	Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. 1989 , 72, 173-7		37
296	Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. 1989 , 73, 369-74		52

295	Blastic transformation of essential thrombocythemia. A case report. 1989 , 39, 670-6	
294	Low protein S in essential thrombocythemia with thrombosis. 1989 , 32, 88-93	20
293	Iron stores in essential thrombocythaemia. A study of 26 patients. 1989 , 58, 291-4	4
292	Polycythemia vera. A clinical study of 141 patients. 1989 , 59, 493-500	34
291	Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. 1989 , 43, 57-65	67
290	Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia. 1990 , 3, 103-7	7
289	Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura. 1990 , 74, 395-401	53
288	DNA content and nuclear size of megakaryocytes in thrombocythaemia. 1990 , 98, 845-50	10
287	Essential thrombocythemia in a cat. 1990 , 4, 87-91	14
286	Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia. 1990 , 60, 37-40	12
285	Clinical course of essential thrombocythemia in 147 cases. 1990 , 66, 549-56	262
284	Thrombocytosis and Thrombocythemia. 1990 , 4, 157-178	59
283	Hematologic disorders and ischemic stroke. A selective review. 1990 , 21, 1111-21	183
282	Chronic myeloproliferative disorders in bone marrow biopsies. 1990 , 186, 3-27	92
281	Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. 1990 , 49, 57-67	60
280	Hemostatic complications in young patients with essential thrombocythemia. 1990 , 88, 371-5	65
279	Cutaneous manifestations in patients with essential thrombocythemia. 1991 , 24, 59-63	59
278	Thrombocythemia and coronary artery disease. 1991 , 122, 573-6	68

277	Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia. 1991 , 54, 21-5	12
276	alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. 1991 , 27 Suppl 4, S69-71	8
275	Circulating activated platelets in myeloproliferative disorders. 1991 , 61, 271-8	66
274	Essential thrombocythemia in young adults. 1991 , 66, 149-54	86
273	Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients. 1991 , 4, 351-4	3
272	Primary thrombocythaemia: diagnosis and management. 1991 , 78, 145-8	52
271	Maintenance therapy in the myeloproliferative disorders: the current options. 1991 , 79 Suppl 1, 92-5	16
270	Primary thrombocythaemia in pregnancy. 1991 , 77, 371-4	46
269	Platelet thrombospondin and glycoprotein IV abnormalities in patients with essential thrombocythemia: effect of alpha-interferon treatment. 1991 , 38, 307-13	18
268	Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. 1991 , 67, 2658-63	224
267	Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. 1991 , 67, 2926-30	130
266	Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview. 1991 , 418, 87-97	31
265	Low-dose aclarubicin in blastic transformation of essential thrombocythemia. 1991 , 62, 194-5	5
264	Interferon alpha-2b in the long-term treatment of essential thrombocythemia. 1991 , 63, 206-9	24
263	Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. 1991 , 63, 101-6	100
262	High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. 1992 , 7, 251-5	50
261	Clinical aspects of chronic myeloproliferative diseases. 1992 , 304, 109-24	1
260	Deletion of the long arm of chromosome 5 in essential thrombocythemia. 1992 , 61, 93-5	9

259	The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states. 1992 , 64, 273-6	49
258	Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. 1992 , 64, 286-91	37
257	Coexistence of essential thrombocythemia and multiple myeloma. 1992 , 65, 103-5	12
256	Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. 1992 , 65, 17-21	18
255	A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. 1992 , 64, 207-9	28
254	Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. 1992 , 40, 283-9	22
253	Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. 1992 , 41, 249-51	34
252	Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders. 1993 , 72, 1209-18	22
251	Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia. 1993 , 43, 78-9	33
250	Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications. 1993 , 83, 192-7	94
249	MCNU in the treatment of essential thrombocythemia--a pilot study. 1993 , 66, 247-9	6
248	Primary thrombocythemia: diagnosis, clinical manifestations and management. 1993 , 67, 57-62	64
247	Marked thrombocytosis with chromosomal abnormalities in a patient with rheumatoid arthritis. 1993 , 12, 529-31	1
246	Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. 1993 , 189, 121-32	59
245	Near-octaploidy in essential thrombocythemia. 1993 , 65, 74-5	5
244	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1993. A 49-year-old man with myelofibrosis, myeloid metaplasia, and osteolytic lesions of the left femur. 1993 , 329, 417-23	1
243	Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis. 1993 , 9, 423-6	25
242	Abnormalities of hemostasis in ischemic stroke. 1993 , 77, 77-94	16

241	Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion. 1994 , 47, 769-70	12
240	Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. 1994 , 68, 153-8	36
239	Essential thrombocythemia and ischemic stroke: report of six cases. 1994 , 15, 359-62	8
238	Essential thrombocythemia and pregnancy. 1994 , 45, 348-9	3
237	Familial myeloproliferative syndrome. 1994 , 46, 225-9	53
236	Immunohistochemical characterization of the mitotic proliferation phenomenon in Sneddon's syndrome and essential thrombocythaemia. 1994 , 131, 814-21	13
235	Studies of neutrophil and monocyte oxidative responses in polycythaemia vera and related myeloproliferative disorders. 1994 , 87, 464-70	18
234	Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. 1994 , 96, 247-53	175
233	Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. 1994 , 97, 374-8	93
232	Issues in the diagnosis and management of essential thrombocythemia. 1994 , 69, 651-5	36
231	Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. 1995 , 91, 618-24	31
230	Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. 1995 , 48, 163-7	14
229	Essential thrombocythemia: a retrospective analysis of 39 cases. 1995 , 49, 39-42	22
228	Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. 1995 , 49, 289-93	37
227	Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. 1995 , 75, 471-7	35
226	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. 1995 , 20, 203-22	62
225	Primary thrombocythemia: a current perspective. 1995 , 13, 355-9	6
224	Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. 1995 , 332, 1132-6	687

223	Multiple myeloma following essential thrombocythemia. 1995 , 20, 177-9	8
222	Treatment of essential thrombocythemia with anagrelide. 1995 , 127, 495-8	18
221	Essential thrombocytosis: underemphasized cause of large-vessel thrombosis. 1995 , 22, 443-7; discussion 448-9	38
220	Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. 1996 , 52, 14-20	55
219	Essential thrombocythaemia: a cause of Sneddon's syndrome. 1996 , 347, 395	3
218	Essential thrombocythemia in an infant. 1996 , 18, 381-3	9
217	Essential thrombocythemia with BCR/ABL rearrangement. 1996 , 89, 74-6	34
216	Unusual chromosome aberration, t(13;14)(q32;q32.3), in a case of essential thrombocythemia with extreme thrombocytosis. 1996 , 91, 68-70	4
215	Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. 1996 , 51, 137-40	26
214	Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. 1996 , 53, 6-10	35
213	Risk factors for essential thrombocythemia: A case-control study. Italian Leukemia Study Group. 1996 , 77, 2157-61	16
212	Serum thrombopoietin level in various hematological diseases. 1996 , 14, 558-65	48
211	Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. 1996 , 22, 303-17	75
210	Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. 1996 , 22 Suppl 1, 65-70	18
209	Transformation of essential thrombocythaemia to T cell acute lymphoblastic leukaemia. 1996 , 20, 347-9	9
208	Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. 1996 , 22 Suppl 1, 41-5	59
207	Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. 1996 , 22 Suppl 1, 149-60	46
206	Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. 1996 , 22 Suppl 1, 71-8	45

205	Interferon-alpha in the treatment of essential thrombocythemia. 1996 , 22 Suppl 1, 135-42		66
204	Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. 1996 , 22 Suppl 1, 47-56		59
203	The Management of Essential Thrombocythaemia. 1997 , 2, 91-100		1
202	Inapparent polycythemia vera: an unrecognized diagnosis. 1997 , 102, 14-20		56
201	Platelet distribution width for differential diagnosis of thrombocytosis. 1997 , 43, 1072-1076		77
200	Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia. <i>Blood</i> , 1997 , 90, 4031-4038	2.2	174
199	BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation. <i>Blood</i> , 1997 , 90, 2768-2771	2.2	42
198	Thrombotic complications in essential thrombocythemia with relatively low platelet counts. 1997 , 56, 168-72		83
197	Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. 1998 , 57, 277-82		28
196	Early cutaneous lesions secondary to hydroxyurea therapy. 1998 , 58, 82-3		4
195	Successful treatment of essential thrombocythemia with anagrelide in a child. 1998 , 30, 367-70; discussion 370-1		9
194	Should a platelet limit of $600 \times 10^9/l$ be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. 1998 , 100, 15-23		106
193	No treatment for low-risk thrombocythaemia: results from a prospective study. 1998 , 103, 772-7		116
192	The use of aspirin in polycythaemia vera and primary thrombocythaemia. 1998 , 12, 12-22		21
191	Cerebral vascular accidents in young patients with essential thrombocythemia: relation with other known cardiovascular risk factors. 1998 , 49, 477-81		10
190	Successful treatment of essential thrombocythemia evolving into agnogenic myeloid metaplasia with interferon-alpha. 1998 , 20, 463-6		2
189	Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis. <i>Blood</i> , 1998 , 91, 1288-1294		83
188	Might Essential Thrombocythemia Carry Ph Anomaly?. <i>Blood</i> , 1998 , 91, 3084-3085	2.2	16

187	Essential thrombocythaemia. 1999 , 171, 210-3		3
186	A Large Proportion of Patients With a Diagnosis of Essential Thrombocythemia Do Not Have a Clonal Disorder and May Be at Lower Risk of Thrombotic Complications. <i>Blood</i> , 1999 , 93, 417-424	2.2	185
185	Patients With Essential Thrombocythemia Do Not Express BCR-ABL Transcripts. <i>Blood</i> , 1999 , 93, 2420-2424		18
184	Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. 1999 , 5, 131-5		16
183	Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. 1999 , 5, 30-6		23
182	The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. 1999 , 104, 730-7		151
181	Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. 1999 , 29, 29-35		22
180	Homocysteine levels in polycythaemia vera and essential thrombocythaemia. 1999 , 105, 551-555		36
179	Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature. 1999 , 8, 105-12		16
178	Idiopathic myelofibrosis in a cat and in three dogs. 1999 , 9, 17-24		10
177	Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. 1999 , 134, 392-7		76
176	Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. 1999 , 96, 191-6		29
175	Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia. 2000 , 63, 131-5		12
174	Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. 2000 , 110, 116-24		81
173	Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. 2000 , 110, 577-83		157
172	Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. 2000 , 14, 142-52		36
171	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. 2000 , 111, 943-953		1
170	Management of essential thrombocythaemia during pregnancy. 2000 , 40, 33-7		26

169	Trisomy 8 in essential thrombocythemia in leukemic transformation. 2000 , 116, 84-6		8
168	Acquired DNA mutations associated with in vivo hydroxyurea exposure. <i>Blood</i> , 2000 , 95, 3589-3593	2.2	104
167	Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment. 2000 , 38, 113-20		11
166	Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. 2000 , 36, 533-8		14
165	Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. 2000 , 6, 157-61		19
164	Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. 2001 , 49, 164-6		44
163	Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. 2001 , 76, 427-31		6
162	Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001 , 98, 3249-55	2.2	176
161	The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia. 2001 , 41, 579-84		6
160	Medical Management of a Large Aortic Thrombus in a Young Woman With Essential Thrombocythemia. 2001 , 76, 427-431		17
159	Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. 2001 , 112, 392-6		28
158	Endothelial dysfunction in patients with polycythaemia vera. 2001 , 115, 354-9		38
157	Ischemic stroke of unusual cause: clinical features, etiology and outcome. 2001 , 8, 133-9		74
156	No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia. 2001 , 126, 56-9		15
155	Clonality analysis using X-chromosome inactivation patterns by HUMARA-PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan. 2001 , 29, 202-8		16
154	Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. 2001 , 66, 143-51		93
153	Thrombocytosis and recurrent hepatic outflow obstruction (Budd-Chiari syndrome) after successful thrombolysis: case report and literature review. 2002 , 8, 369-74		3
152	Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. 2002 , 7, 173-7		4

151	Circulating thrombopoietin in clonal versus reactive thrombocytosis. 2002 , 7, 9-12		11
150	The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. <i>Blood</i> , 2002 , 100, 714-7	2.2	37
149	Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. <i>Blood</i> , 2002 , 99, 4131-7	2.2	46
148	Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. 2002 , 68, 112-6		9
147	Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. 2002 , 68, 189-93		28
146	Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. 2002 , 69, 43-9		8
145	Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. 2002 , 69, 185-91		32
144	Pregnancy and abortion in women with essential thrombocythemia. 2002 , 69, 233-4		11
143	Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. 2002 , 70, 283-91		44
142	What is the standard treatment in essential thrombocythemia. 2002 , 76 Suppl 2, 311-7		4
141	Aortic mural thrombus embolization: an unusual presentation of essential thrombocytosis. 2002 , 16, 375-9		11
140	Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. 2002 , 116, 812-6		18
139	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. 2002 , 116, 855-61		32
138	The role of blood component removal in essential and reactive thrombocytosis. 2002 , 6, 36-44		30
137	Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. 2002 , 118, 786-90		111
136	Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients. 2003 , 82, 214-7		6
135	Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia. 2003 , 82, 153-9		18
134	Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. 2003 , 82, 148-52		120

133	Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. 2003 , 71, 377-84		14
132	Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. 2003 , 71, 276-82		6
131	Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. 2003 , 74, 26-31		53
130	Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation. 2003 , 42, 53-60		5
129	Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. 2003 , 123, 517-21		31
128	Bone marrow and peripheral blood C-kit ligand concentrations in patients with thrombocytosis and thrombocytopenia. 2003 , 8, 369-73		2
127	Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. 2003 , 44, 1483-8		4
126	Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. <i>Blood</i> , 2003 , 101, 783	2.2	9
125	Coagulation Abnormalities in Stroke. 2004 , 707-724		
124	Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review. 2004 , 55, 319-23		22
123	Comparison of methods for polycythemia rubra vera-1 mRNA quantification in whole-blood leukocytes and purified granulocytes. 2004 , 50, 644-7		4
122	Therapeutic effectiveness of ranimustine chemotherapy for elderly essential thrombocythemia*. 2004 , 4, 223-228		1
121	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. 2004 , 126, 650-6		26
120	Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. 2004 , 72, 416-9		21
119	Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia. 2004 , 143, 125-9		12
118	Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 2004 , 83, 495-7		22
117	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia. 2004 , 28, 1097-105		3
116	Progressive stroke due to essential thrombocythemia. 2004 , 15, 390-392		6

115	Functional and morphological cardiac changes in myeloproliferative disorders (clinical study). 2004 , 97, 213-20	20
114	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. 2004 , 117, 755-61	355
113	Risk-adapted therapy in essential thrombocythemia and polycythemia vera. 2005 , 19, 243-52	65
112	Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. 2005 , 130, 391-3	10
111	Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. 2005 , 78, 71-3	23
110	Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. 2005 , 44, 47-50	10
109	Essential thrombocythemia. <i>Seminars in Hematology</i> , 2005 , 42, 230-8	4 39
108	Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. 2006 , 18, 187-90	23
107	Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. 2006 , 47, 1774-81	62
106	Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?. 2006 , 47, 1724-5	3
105	A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. 2006 , 47, 381-96	38
104	Thrombocythie essentielle. Critères du diagnostic. Stratification pronostique. Bauche de stratégie thérapeutique. 2006 , 1, 1-19	0
103	Hematological malignancy and pregnancy: a single-institution experience of 21 cases. 2006 , 28, 170-6	31
102	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. 2006 , 107, 2206-11	74
101	Best practice in primary care pathology: review 3. 2006 , 59, 781-9	27
100	Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. 2007 , 102, 2464-70	218
99	Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). 2007 , 55, 92-104	25
98	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. <i>Blood</i> , 2007 , 110, 485-9	2.2 131

97	Thrombocytosis: Essential Thrombocythemia and Reactive Causes. 2007 , 295-318	
96	Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. 2007 , 25, 115-20	25
95	JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. 2007 , 86, 793-800	18
94	Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. 2008 , 22, 14-22	780
93	Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. 2008 , 38, 422-6	15
92	Benign familial microcytic thrombocytosis with autosomal dominant transmission. 1997 , 52, 47-50	13
91	Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. 2008 , 74, 10-16	1
90	BCR rearrangement in apparent essential thrombocythaemia. 1993 , 85, 625-6	10
89	Familial thrombocytosis. 1995 , 89, 900-2	32
88	Myeloproliferative Disorders. 2008 , 656-664	
87	Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. 2008 , 13, 195-202	28
86	Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. <i>Blood</i> , 2008 , 111, 666-71	2.2 88
85	Postsplenectomy reactive thrombocytosis. 2009 , 22, 9-12	61
84	[Evaluation of platelet indices for differential diagnosis of thrombocytosis by ADVIA 120]. 2009 , 29, 505-9	13
83	Nonatherosclerotic Vasculopathies. 2009 , 389-445	2
82	Evaluation of superoxide dismutase enzyme activity of polymorphonuclear leucocytes, erythrocytes and thrombocytes in patients with chronic myeloproliferative disorders. 2009 , 37, 1365-74	1
81	Use of splenic volume estimation to distinguish primary thrombocythaemia from reactive thrombocytosis. 1988 , 40, 339-42	15
80	Spontaneous remission of essential thrombocythaemia during two consecutive pregnancies. 1989 , 43, 348-9	1

79	Circulating erythroid and megakaryocytic progenitors in polycythaemia vera and essential thrombocythaemia. 1989 , 43, 417-22	11
78	Qualitative platelet defects in chronic myeloproliferative disorders: evidence for reduced ATP secretion. 1989 , 43, 435-40	17
77	Reversal of myelofibrosis by hydroxyurea. 1990 , 44, 33-8	74
76	The management of thrombocytosis. 1990 , 44, 81-8	33
75	Platelets of patients affected with essential thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. 1990 , 44, 116-20	22
74	Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. 1992 , 48, 33-6	16
73	The in vitro effects of interferon-gamma, interferon-alpha, and tumour-necrosis factor-alpha on erythroid burst-forming unit growth in patients with non-leukaemic myeloproliferative disorders. 1993 , 50, 250-4	7
72	Measurement of spleen size using gamma camera scintigraphy in essential thrombocythaemia. 1993 , 51, 141-3	7
71	Stimulus-specific defect in platelet aggregation in polycythemia vera. 1994 , 53, 145-9	11
70	Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. 1994 , 52, 134-9	113
69	Erythropoietin concentration in the serum from patients with primary thrombocythaemia. 1995 , 55, 272-3	6
68	Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?. 1995 , 54, 21-6	37
67	Low-dose interferon alpha treatment in essential thrombocythemia. 2009 , 56, 104-105	1
66	Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. 1996 , 56, 287-92	14
65	Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. 1996 , 56, 158-62	13
64	Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. 1998 , 60, 278-82	43
63	Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. 1998 , 61, 119-22	20
62	Hydroxyurea as a cause of drug fever in essential thrombocythaemia. 1999 , 62, 354-5	9

61	AML transformation in 56 patients with Ph- MPD in two well defined populations. 2009 , 82, 106-11	52
60	Prodromal myeloproliferative neoplasms: the 2008 WHO classification. 2010 , 85, 62-9	67
59	The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. 2009 , 115, 3842-7	180
58	Essential thrombocythemia: past and present. 2009 , 4, 381-8	21
57	Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. 2010 , 91, 174-9	79
56	Genotypic and phenotypic classification of cancer: How should the impact of the two diagnostic approaches best be balanced?. 2010 , 49, 763-74	5
55	Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. 2010 , 56, 758-67	57
54	Myeloproliferative neoplasms cause glomerulopathy. 2011 , 80, 753-9	66
53	Acquired disorders affecting megakaryocytes and platelets. 2011 , 523-545	1
52	Evaluation of the bioactive and total transforming growth factor β levels in primary myelofibrosis. 2011 , 53, 100-6	22
51	Emerging treatments for essential thrombocythemia. 2011 , 2, 151-9	2
50	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 2011 , 96, 454-8	53
49	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 2011 , 96, 367-74	60
48	Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. 2011 , 152, 81-8	55
47	The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. 2011 , 86, 148-55	49
46	Assessment of left ventricular myocardial performance by tissue Doppler echocardiography in patients with polycythemia vera. 2011 , 28, 948-54	1
45	Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. 2011 , 86, 974-9	31
44	Correction. 2012 , 65, 95.1-95	13

43	An ulceronecrotic foot lesion in a patient with essential thrombocythemia: successful treatment with hydroxyurea. 2012 , 4, 10-3		6
42	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012 , 120, 5128-33; quiz 5252	2.2	34 ⁰
41	Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. 2012 , 49, 170-6		36
40	Electrocardiographic findings in patients with polycythemia vera. 2012 , 9, 93-102		2
39	Leukaemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms: are Asian patients different?. 2012 , 42, 513-7		0
38	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. 2013 , 37, 162-8		22
37	Thrombocytosis. 2013 , 298-323		2
36	Off-pump myocardial revascularization in a high-risk patient with essential thrombocythemia. 2014 , 41, 537-42		6
35	Papillary muscle rupture associated to essential thrombocytosis. 2014 , 32, 1556.e1-2		
34	Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. 2015 , 35, 2042-9		29
33	Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. 2017 , 42, 306.e5-306.e10		1
32	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. 2017 , 58, 2786-2798		12
31	Acute myocardial infarction following sequential multi-vessel occlusion in a case of polycythemia vera. 2019 , 20, 111-114		3
30	MYELOPROLIFERATIVE AND MYELOYDYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS AND RELATED CONDITIONS. 2019 , 267-345		
29	Thrombocytosis: Essential Thrombocythemia and Reactive Causes. 2019 , 346-373		
28	Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. 2021 , 35, 1643-1660		10
27	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402		1
26	The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. 1998 , 102, 00-00		2

25	The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. 2000 , 111, 943-953		19
24	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". 2020 , 105, 335-343		1
23	Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. 1990 , 74, 10-6		41
22	Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases. 1995 , 26, 1463-6		45
21	Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder. 1988 , 81, 1999-2003		18
20	BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation. <i>Blood</i> , 1997 , 90, 2768-2771	2.2	3
19	A Large Proportion of Patients With a Diagnosis of Essential Thrombocythemia Do Not Have a Clonal Disorder and May Be at Lower Risk of Thrombotic Complications. <i>Blood</i> , 1999 , 93, 417-424	2.2	8
18	Acquired DNA mutations associated with in vivo hydroxyurea exposure. <i>Blood</i> , 2000 , 95, 3589-3593	2.2	2
17	Introduction: Towards a Molecular Classification of Chronic Myeloproliferative Disorders. 2004 , 3-9		
16	Chronic myeloid disorders, excluding CML. 2004 , 735-752		
15	An overview of hemostasis and thrombosis. 2007 , 1-29		
14	Differential diagnosis [chromosomal/molecular changes]. 2008 , 542-566		
13	Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. 2010 , 293-312		
12	Bone marrow. 2011 , 1927-2012		
11	Do We Need Biological Studies for Patient Management?. 2012 , 11-16		
10	Zur Behandlung myeloproliferativer Syndrome mit Interferonen. 1990 , 215-233		3
9	Recombinant Interferon- β but not Interferon- α is Effective Therapy for Essential Thrombocythemia. 1990 , 569-574		
8	Chronisch-myeloproliferative Erkrankungen. 1992 , 283-333		

- 7 Sustained Remission After Interferon Treatment for Essential Thrombocythemia. **1993**, 159-162
- 6 Blutungs- und Thromboseneigung bei Thrombozythämien. **1993**, 284-291
- 5 Interferon Therapy of Essential Thrombocythemia and Polycythemia Vera. **1997**, 67-83
- 4 Patients With Essential Thrombocythemia Do Not Express BCR-ABL Transcripts. *Blood*, **1999**, 93, 2420-2421
- 3 Essential Thrombocythemia. **2007**, 321-348
- 2 Common emergencies in cancer medicine: hematologic and gastrointestinal syndromes. *Journal of the National Medical Association*, **1992**, 84, 165-76 2.3 4
- 1 The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. *Cancers*, **2021**, 13, 6.6 0